RANI Rani Therapeutics Holdings: Enterprise Value to EBITDA Ratio
Rani Therapeutics (RANI) business relies on exclusive patents in the field of robotic capsules, backed by strong biotech support and strict FDA oversight. This daily price chart based on the EV/EBITDA metric is currently at 0.00. Rani Therapeutics (RANI) is developing innovative "robo-pills" to eliminate injections, anticipating long-term revenue from licensing this unique drug delivery system.
Comprehensive metric breakdowns and analytics for ranitherapeutics.com (RANI)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Rani Therapeutics|RANI - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Rani Therapeutics Holdings, Inc.|RANI - Aggregate Debt Obligations|Debts to Book Capitalization RANI|RANI - Company Long-Term Debts|Company Short-Term Debt Rani Therapeutics|Quick Ratio ranitherapeutics.com
- financial results and valuation multiples details:
RANI - Net Financial Result|Future Profit Rani Therapeutics|RANI - Company Value to Net Income|Projected Price to Earnings Rani Therapeutics Holdings, Inc.|RANI - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple RANI|RANI - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Rani Therapeutics|RANI - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months ranitherapeutics.com|RANI - Earnings per share increase in current year|Earnings growth forecast for next year Rani Therapeutics
Summary company analysis:Rani Therapeutics Inc RANI
The specificity of Rani Therapeutics (RANI) lies in the application of a universal biologic delivery platform across various molecules, which necessitates an assessment of infrastructure capital intensity. The EV/EBITDA ratio trajectory compares the total enterprise value, including debt, against operating profit, allowing investors to identify the real value of assets and avoid capital impairment risks associated with hidden debt loads.
Competitors of Rani Therapeutics
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|Business Value to Operating Income Before Depreciation MNKD|Amphastar - EV/EBITDA Multiple|PCRX - EV/EBITDA Multiple|ARS Pharmaceuticals (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation TBPH|AQST (Aquestive Therapeutics, Inc.) - EV/EBITDA Multiple|scPharma (SCPH) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharmaceuticals Holding) - Business Value to Operating Income Before Depreciation|China SXT Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio EPRX (Eupraxia Pharmaceuticals, Inc.)|BioHarvest Sciences Inc. - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation EXOZ (Invizyne Technologies)|ORMP: EV/EBITDA Multiple|Company Value to EBITDA Entera Bio (ENTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MindWalk Holdings|ABVC: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CPIX|EV/EBITDA Multiple Quantum BioPharma Ltd. (QNTM)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FibroGen Corp FGEN|TELO (Telomir Pharmaceuticals Corp) - Company Value to Operating Income Before Depreciation Ratio|Synergy CHC Corporation - EV/EBITDA Multiple|Company Value to EBITDA Rallybio Corporation|LEXX (lexariabioscience.com) - Enterprise Value to EBITDA Ratio|Pulmatrix Inc (PULM) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio PTHL|APM (Aptorum) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple LYRA|Total Company Value to Operating Income Before Depreciation Ratio impactbiomedinc.com|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals, Inc.)|YCBD - Enterprise Value to EBITDA Ratio|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Altamira Therapeutics CYTO|Lipella Pharmaceuticals (LIPO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|optinose.com - Business Value to Operating Income Before Depreciation|PIRS (Pieris Pharmaceuticals, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Procaps Group|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Petros (PTPI)|Qilian International Corp - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple SLRN (Acelyrin, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio tffpharma.com (TFFP)
